2019-07-02T15:14:38-05:00 2018-12-31 561743537 LANGDON & COMPANY LLP 223 US HIGHWAY 70 EAST SUITE 100 GARNER NC 275294051 990 2018-01-01 208423943 CHORDOMA FOUNDATION CHOR 9198096779 PO BOX 2127 DURHAM NC 27702 JOSH SOMMER PRESIDENT 9198096779 2019-06-27 true ANTHONY T PANDISCIA P00187421 9196621001 2019-07-02 12.105.62.70 2019-07-02 15:14:38 CD P 52B825F0329884C4B262C317B25CCBB44E5336EA 66C4394A30B6EB4D875EC41D639AD3BE1C3CA6A8 2018 2020-03-31 21:24:44Z JOSH SOMMER PO BOX 2127 DURHAM NC 27702 2901266 false X WWW.CHORDOMAFOUNDATION.ORG X 2007 NC THE MISSION OF THE CHORDOMA FOUNDATION IS TO IMPROVE THE LIVES OF THOSE AFFECTED BY CHORDOMA AND LEAD THE SEARCH FOR A CURE. 11 10 10 108 0 2013420 2350245 4345 11150 3685 1988 54822 57806 2076272 2421189 1343996 699940 0 880506 930791 46000 439268 695133 662150 2919635 2338881 -843363 82308 4843261 4518951 1408278 1032256 3434983 3486695 X THE MISSION OF THE CHORDOMA FOUNDATION IS TO IMPROVE THE LIVES OF THOSE AFFECTED BY CHORDOMA AND LEAD THE SEARCH FOR A CURE. false false 1306670 692109 (RESEARCH) TO ACCELERATE THE DEVELOPMENT OF BETTER TREATMENTS FOR CHORDOMA, THE CHORDOMA FOUNDATION INITIATED AND FUNDED A PORTFOLIO OF RESEARCH PROJECTS SPANNING BASIC, TRANSLATIONAL AND CLINICAL SCIENCE, AND PROVIDED A VARIETY OF VITAL SERVICES TO THE CHORDOMA RESEARCH COMMUNITY, INCLUDING BANKING CHORDOMA TUMOR TISSUE, DEVELOPING AND DISTRIBUTING PRECLINICAL MODELS OF CHORDOMA, PERFORMING PRECLINICAL DRUG SCREENING, AND FACILITATING PATIENT PARTICIPATION IN CLINICAL TRIALS. 307642 2607 11150 (PATIENT SERVICES) TO IMPROVE THE LIVES OF INDIVIDUALS AFFECTED BY CHORDOMA, THE CHORDOMA FOUNDATION HELPED PATIENTS AND THEIR FAMILIES FIND ACCURATE INFORMATION ABOUT CHORDOMA AND TREATMENT OPTIONS, OVERCOME BARRIERS TO CARE, AND GET EMOTIONAL SUPPORT FROM PEERS. THIS INCLUDED DEVELOPING AND DISTRIBUTING EDUCATIONAL CONTENT, PROVIDING PATIENT NAVIGATION SERVICES, HOSTING EDUCATIONAL CONFERENCES, AND OPERATING AN ONLINE COMMUNITY FORUM FOR PATIENTS AND FAMILIES. OTHER PROGRAM SERVICE ACCOMPLISHMENTS 1614312 true true false false false false false false false false true false false false false true true false false false true true false true false false false true false true false false false false false false false true true false false false false false false false false true 12 0 true 10 true false false false false false false false false false false false false false false X 11 10 false false false false false false false true true false false true true true true true true true true false X X X JOSH SOMMER 9198096779 PO BOX 2127 DURHAM NC 27702 X JOSH SOMMER PRESIDENT 60.00 X X 99097 0 7377 JOEL BECKMAN VICE CHAIR 10.00 X 0 0 0 PAULA SONG DIRECTOR 2.00 X 0 0 0 ANDY SCHOELKOPF DIRECTOR 8.00 X 0 0 0 KERRY SHAD SECRETARY 2.00 X 0 0 0 DAVID SANDAK CHAIR 4.00 X 0 0 0 DAVID DREWRY DIRECTOR 4.00 X 0 0 0 CHRISTY SHAFFER DIRECTOR 2.00 X 0 0 0 INGEMAR LANEVI TREASURER 2.00 X 0 0 0 STEVEN MANDEL DIRECTOR 2.00 X 0 0 0 SHREYAS PATEL DIRECTOR 2.00 X 0 0 0 JOAN LEVY DIRECTOR OF 40.00 X 155977 0 20400 255074 27777 1 false true false 2350245 65411 2350245 COMMUNITY CONFERENCE 11150 11150 11150 4180 4180 477885 480077 -2192 -2192 -2192 OTHER REVENUE 57806 57806 57806 2421189 55614 15330 549940 549940 150000 150000 115885 63888 16750 35247 666169 401160 102974 162035 91867 50221 21011 20635 56870 32630 9872 14368 2029 2029 13926 9510 1742 2674 46000 46000 90133 31461 22552 36120 16985 2215 4428 10342 39149 15591 4330 19228 132854 64636 25396 42822 31942 12721 3533 15688 78757 40817 19642 18298 5360 3216 911 1233 16125 8118 6745 1262 EVENTS 143060 125608 6165 11287 BAD DEBT EXPENSE 39250 39250 RESEARCH MATERIALS 30705 30705 BIOSPECIMEN DISTRIBUTION 21875 21875 2338881 1614312 285301 439268 1828573 2056355 343035 185825 2431372 2144523 176155 85806 37935 24136 42870 23541 23214 19329 2977 2977 4843261 4518951 117401 180424 1279067 844782 11810 7050 1408278 1032256 X 1347949 1516964 2087034 1969731 3434983 3486695 4843261 4518951 X 82308 -30596 X false true X true false X 2011406 1915121 4144568 2013420 2346756 12431271 2011406 1915121 4144568 2013420 2346756 12431271 4842351 7588920 513 711 439 3685 4180 9528 15044 4345 4180 23569 12464368 112628 0.60880 0.54530 X PART II, LINE 10 OTHER INCOME 23,569 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4463 2590 1873 38407 20951 17456 19329 X 2463731 130944 -88402 42542 2421189 2421189 2412019 130944 -57806 73138 2338881 2338881 SCHEDULE D, PAGE 3, PART X THE ORGANIZATION EVALUATES ITS UNCERTAIN TAX POSITIONS USING THE PROVISIONS OF ASC 740-10-25, RECOGNITION OF A TAX POSITION. ACCORDINGLY, THE ORGANIZATION POLICY IS TO RECORD A LIABILITY FOR ANY TAX POSITION TAKEN THAT IS BENEFICIAL TO THE ORGANIZATION, INCLUDING ANY RELATED INTEREST AND PENALTIES, WHEN IT IS MORE LIKELY THAN NOT THE POSITION OF MANAGEMENT, WITH RESPECT TO A TRANSACTION OR CLASS OF TRANSACTIONS, WILL BE OVERTURNED BY A TAXING AUTHORITY UPON EXAMINATION. MANAGEMENT BELIEVES THERE ARE NO SUCH POSITIONS AS OF DECEMEBR 31, 2018. SCHEDULE D, PAGE 4, PART XI, LINE 2D LOSS ON CURRENCY TRANSLATION -30,596 RECLASS OF NEGATIVE GRANT EXPENSE -57,806 SCHEDULE D, PAGE 4, PART XII, LINE 2D RECLASS OF NEGATIVE GRANT EXPENSE -57,806 true EUROPE GRANTS RESEARCH 150000 150000 150000 RESEARCH 150000 WIRE TRANSFER 1 false false false false false false SCHEDULE F, PAGE 1, PART I, LINE 2 MONITORING THE USE OF GRANT FUNDS OUTSIDE THE U.S. IS CARRIED OUT THROUGH REGULAR REPORTING BY GRANTEE ORGANIZATIONS. SCHEDULE F, PAGE 1, PART I, LINE 3 EUROPE 150,000 0 SCHEDULE F, PAGE 5, PART V 150,000 WAS AWARDED TO DR. DENIS MURPHY AND DR. OPHER GILEADI AT THE UNIVERSITY OF OXFORD IN UNITED KINGDOM TO BE USED FOR DEVELOPING A STRUCTURE-GUIDED DRUG DISCOVERY PIPELINE FOR DIRECT BRACHYURY INHIBITION. X X X X X true ZANELLA 112 HELLER PARKWAY NEWARK NJ 07104 CONSULTING false 46000 -46000 46000 -46000 AL AR AK CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI SCHEDULE G, PAGE 1, PART I, LINE 2B, COLUMN (V) ZANELLA CONSULTING AGREEMENT WITH ZANELLA true START 4383 MEDICAL DRIVE SUITE 4021 SAN ANTONIO TX 78229 208313687 183901 RESEARCH GRANT MASSACHUSETTS GEN HOSPITAL 185 CAMBRIDGE ST BOSTON MA 02114 041564655 501C3 50000 RESEARCH GRANT VALA SCIENCES 6370 NANCY RIDGE DRIVE 106 SAN DIEGO CA 92121 200906350 14900 RESEARCH GRANT JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501C3 20032 RESEARCH GRANT UNIVERSITY OF CALIFORNIA SF 220 MONTGOMERY STREET SAN FRANCISCO CA 94104 942829914 501C3 10000 RESEARCH GRANT UNIVERSITY OF MICHIGAN 1150 E MEDICAL CENTER DR ANN ARBOR MI 48109 386006309 501C3 25000 RESEARCH GRANT YALE UNIVERSITY PO BOX 208103 NEW HAVEN CT 06520 060646973 501C3 150000 RESEARCH GRANT CHILDREN'S HOSPITAL OF PHILADELPHIA CHOP 3615 CIVIC CENTER BOULEVARD PHILADELPHIA PA 19104 231352166 501C3 60916 RESEARCH GRANT CLINICAL RESEARCH SEQUENCING 415 MAIN STREET CAMBRIDGE MA 02142 352469571 LLC 18750 RESEARCH GRANT 6 SCHEDULE I, PAGE 1, PART I, LINE 2 MONITORING USE OF GRANT FUNDS INSIDE THE U.S. IS CARRIED OUT THROUGH REGULAR REPORTING BY GRANTEE ORGANIZATIONS. X X false false false false false false false false false JOAN LEVY DIRECTOR OF RESEARCH 155977 20400 155977 20400 ANDREW SCHOELKOPF BOARD DIRECTOR 65000 CONTRIBUTION false STEVEN MANDEL BOARD DIRECTOR 21437 CONTRIBUTION false DAVID DREWRY BOARD DIRECTOR 1109 CONTRIBUTION false INGEMAR LANEVI BOARD DIRECTOR 4563 CONTRIBUTION false SMITH ANDERSON LLP BOARD DIRECTOR 20729 IN-KIND LEGAL SVCS false SCHEDULE L, PART V THE FOUNDATION RECEIVED AN IN-KIND DONATION OF LEGAL SERVICES FROM SMITH ANDERSON, LLP. KERRY SHAD, A BOARD MEMBER OF THE FOUNDATION, IS ALSO A MEMBER OF THE LAW FIRM SMITH ANDERSON, LLP. THE FOUNDATIONS' BOARD MEMBERS AND FORMER BOARD MEMBERS PROVIDED CONTRIBUTIONS TOTALING 92,109. THE FUNDS ARE TREATED THE SAME AS A PLEDGE OR CONTRIBUTION FROM AN UNRELATED OR UNINTERESTED PARTY. X 1 29949 FMV X TECH SOLUTIONS 1 35462 FMV false true false FORM 990, PAGE 2, PART III, LINE 4D OTHER PROGRAM SERVICE ACCOMPLISHMENTS FORM 990, PAGE 6, PART VI, LINE 11B FINANCIAL REPORTS AND THE FORM 990 ARE REVIEWED BY THE FOUNDATION'S EXECUTIVE DIRECTOR, BOARD CHAIR AND FINANCE COMMITTEE BEFORE BEING DISTRIBUTED TO THE FULL BOARD FOR REVIEW AND APPROVAL. FORM 990, PAGE 6, PART VI, LINE 12C EACH EMPLOYEE, DIRECTOR, OR OTHER AGENT OF THE FOUNDATION ANNUALLY SIGNS A STATEMENT THAT AFFIRMS THEY HAVE RECEIVED A COPY OF THE POLICY, READ AND UNDERSTAND THE POLICY, AGREED TO COMPLY WITH THE POLICY, AND UNDERSTAND THE FOUNDATION MUST ENGAGE PRIMARILY IN ACTIVITIES THAT ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES IN ORDER TO MAINTAIN THEIR FEDERAL TAX EXEMPTION. FORM 990, PAGE 6, PART VI, LINE 15A THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS RECOMMENDS COMPENSATION OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES THAT IS (I) WITHIN THE BUDGET APPROVED BY THE BOARD OF DIRECTORS, AND (II) COMPARABLE TO INDUSTRY NORMS FOR SIMILARLY SIZED NONPROFITS. THE BOARD OF DIRECTORS DECIDE ON COMPENSATION OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES BY VOTE. FORM 990, PAGE 6, PART VI, LINE 15B THE EXECUTIVE DIRECTOR, ALONG WITH THE BOARD OF DIRECTORS, DETERMINE THE COMPENSATION OF THE ORGANIZATION'S EMPLOYEES AFTER CAREFULLY REVIEWING THE EMPLOYEE CREDENTIALS AND THE ORGANIZATION'S BUDGET. ALL POSITIONS AND COMPENSATIONS ARE APPROVED AND FUNDED THROUGH THE ANNUAL BUDGET, WHICH REQUIRES BOARD REVIEW AND APPROVAL. IN ADDITION, PERSONNEL ISSUES MAY BE BROUGHT BEFORE THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS BY THE EXECUTIVE DIRECTOR. FORM 990, PAGE 6, PART VI, LINE 19 GOVERNING DOCUMENTS, DISCLOSURE EXPLANATION, ARTICLES OF INCORPORATION, BY-LAWS, POLICIES AND PROCEDURES MANUAL, CONFLICT OF INTEREST POLICY AND OTHER GOVERNING POLICIES, ANNUAL AUDITS AND 990'S ARE ON FILE IN THE FINANCE OFFICE, AVAILABLE ON THE FOUNDATION'S WEBSITE AND AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART VII BOARD MEMBER, KERRY SHAD, RESIGNED FROM HER POSITION OF SECRETARY ON NOVEMBER 4, 2018. THE POSITION HAS NOT BEEN FILLED SINCE THEN. FORM 990, PART XI, LINE 9 LOSS ON CURRENCY TRANSLATION -30,596 RECLASS OF NEGATIVE GRANT EXPENSE -57,806 RECLASS OF NEGATIVE GRANT EXPENSE 57,806 TOTAL -30,596